Given the clinical implications, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA.
The Seraseq Triple X SYndrome (XXX) Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow, and ensure overall proficiency with the same sustainable product.
Matched (or related) maternal-fetal Triple X Syndrome (or Trisomy XXX) sample compatible with a broad range of NIPT assay methods
Proprietary method maintains native cfDNA characteristics such as size profile of ~170 bp, size distribution, SNP content, and natural maternal-fetal size difference,
Offered in a plasma format capable of assessing the entire workflow from extraction through analysis (identical to clinical samples)
Long shelf-life and lot-to-lot consistency with high-quality materials manufactured in GMP-compliant and ISO 13485-certified facilities under strict quality checks,
Customization of fetal fraction, concentration, and material formulation (either in plasma or fragmented DNA in buffer format) available on request.
